Molecular and biologic markers of premalignant lesions of human breast

Advances in Anatomic Pathology

Volumn 9, Issue 3, 2002, Pages 185-197

  Krishnamurthy, Savitri ^a   Sneige, Nour ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; Breast cancer; Premaligant lesions in breast

Indexed keywords

TUMOR MARKER;

BREAST; BREAST TUMOR; CARCINOMA IN SITU; GENETIC MARKER; GENETICS; HYPERPLASIA; METABOLISM; PATHOLOGY; PRECANCER; REVIEW;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; GENETIC MARKERS; HYPERPLASIA; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036582558     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200205000-00002     Document Type: Review

References (124)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
2. DeOme KB, Faulin LJ, Bern HA, et al. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 1959;19:515-20.
3. Morris DW, Cardiff RD. The multistep model of mouse mammary tumor development. Adv Virol Oncol 1987;7:123-40.
4. Dawson PJ, Wolman SR, Tait L, et al. MCFIOAT: a model for the evolution of cancer from proliferation breast disease. Am J Pathol 1996;148:313-9.
5. Foote FW, Stewart FW. Comparative studies of cancerous versus noncancerous breasts. Ann Surg 1945;121:197-222.
6. Ryan JA, Cody CV. Intraductal epithelial proliferation in the human breast - a comparative study. Cancer J Surg 1962;5:12-8.
7. Karpas CM, Leis HP, Oppenheim A, et al. Relationship of fibrocystic disease to carcinoma of the breast. Ann Surg 1995;162:1-8.
8. Black MM, Barclay TH, Cutler SV, et al. Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer 1972;29:338-43.
9. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51. (Pubitemid 15192861)
10. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990;65:518-29. (Pubitemid 20058370)
11. London SJ, Conolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-4.
12. Page DL, Dupont WD, Rogers LW, et al. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;49:751-8. (Pubitemid 12165434)
13. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 1985;55:2698-708. (Pubitemid 15092160)
14. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65. (Pubitemid 23054916)
15. Henderson BE, Ross R, Bernstein L. Estrogen as a cause of human cancer: The Richard and Hindau Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53. (Pubitemid 18045752)
16. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestins, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 1993;15:17-35. (Pubitemid 23269068)
17. Jordan CV. Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995;36:267-85.
18. Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal precancerous breast. J Pathol 1999;188:237-44. (Pubitemid 29317764)
19. Allegra JC, Lippman ME, Green L, et al. Estrogen receptor values in patients with benign breast disease. Cancer 1979;44:228-31. (Pubitemid 9234936)
20. Peterson OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal nonlactating human breast tissue. J Natl Cancer Inst 1986;77:343-9.
21. Ricketts D, Turnbull L, Tyall G, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991;51:1817-22.
22. Khan SA, Rogers MAM, Khurana KK, et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998;90:37-42. (Pubitemid 28078079)
23. Mohsin SK, Hilsenback SG, Allfred DC. Estrogen receptors and prognosis in premalignant breast disease. Mod Pathol 2000;13:28A.
24. Giri DD, Dundas AC, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistologic study. Histopathology 1989;15:575-84. (Pubitemid 20022907)
25. Visscher DV, Padiyar N, Lang D, et al. Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions. Breast J 1998;4:447-51. (Pubitemid 29018658)
26. Schmitt FC. Multistep progression from an estrogen dependent growth toward autonomous growth in breast carcinogenesis. Eur J Cancer 1995;31(suppl A):2049-52. (Pubitemid 26023096)
27. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 1990;94:533-7. (Pubitemid 20369713)
28. Pallis L, Wilking N, Cedermark B, et al. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 1992;12:2113-5. (Pubitemid 23105416)
29. Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120:81-4.
30. Clark RB, Howell H, Potten CS, et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-91. (Pubitemid 27498105)
31. Shoker BS, Jarvis C, Clarke RB, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999;155:1811-5.
32. Iqbal M, Davies MP, Shoker BS, et al. Subgroups of nonatypical hyperplasia of breast defined by proliferation of estrogen receptor-positive cells. J Pathol 2001;193:333-8. (Pubitemid 32229864)
33. Fuqua SA, Wiltschke C, Zhang ZX, et al. A hypersensitive estrogen receptor - alpha mutation in premalignant breast lesions. Cancer Res 2000;60:4026-9. (Pubitemid 30636577)
34. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47. (Pubitemid 24322246)
35. Thor AD, Moore DHI, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
36. Davidoff AM, Kerns B-JM, Pence JC, et al. p53 alterations in all stages of breast cancer. J Surg Oncol 1991;48:260-7.
37. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31. (Pubitemid 27131374)
38. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-1327. (Pubitemid 23317333)
39. Davidoff AM, Humphery PA, Iglehart JD, et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991a;88:5006-10. (Pubitemid 21914672)
40. Barnes DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild-type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-63.
41. Eriksson ET, Schimmelpenning H, Aspenblad U, et al. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during in transition from benign to malignant breast disease. Hum Pathol 1994;25:1228-33. (Pubitemid 24351507)
42. Rajan PB, Scott DJ, Perry RH, et al. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 1997;42:283-90. (Pubitemid 27091129)
43. Bartek J, Bartkova J, Vojtesek B, et al. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumor in situ and in vitro. Int J Cancer 1990;46:839-44.
44. Hall PA, Ray A, Lemoine NR, et al. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991;338:513.
45. Heyderman E, Dagg B. p53 immunostaining in benign breast cancer. Lancet 1991;338:1532.
46. Younes M, Lebovitz RM, Bommer KE, et al. p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995;26:155-8.
47. Millikan R, Hulka B, Thor A, et al. p53 mutation in benign breast tissue. J Clin Oncol 1995;13:2293-300.
48. Fabian CJ, Kimbr BF, Salles CM, et al. Short-term breast cancer prediction by random periareolar fine needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92:1217-27. (Pubitemid 30627730)
49. Rohan TE, Hartwick W, Miller AB, et al. Immunohistochemical detection of C-erb B-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998;90:1262-9. (Pubitemid 28433470)
50. Umekita T, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, noninvasive and invasive mammary carcinoma: an immunohistochemical study. Virchows Arch 1994;424:491-4. (Pubitemid 24213607)
51. Chitemere M, Andersen TI, Hom R. p53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 1996;41:103-9. (Pubitemid 26360139)
52. Schmitt FC, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995;176:233-241.
53. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification - a study of 127 cases: correlation with estrogen and progesterone receptors p53 and c-erb B-2 proteins and proliferative activity. Semin Diagn Pathol 1994;11:208-14. (Pubitemid 24308081)
54. Domagala W, Markiewski M, Kubiak R, et al. Immunohistochemical profile of invasive lobular carcinoma of the breast predominantly vimentin and p53 protein negative, cathepsin D and estrogen receptor positive. Virchows Arch 1993;423:497-502.
55. Ravdin PM, Chamness GC. The C-erb B-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995;159:19-27.
56. Gusterson BA, Machin LG, Gullick WJ, et al. C-erb B-2 expression in benign and malignant breast disease. Cancer 1998;58:453-7.
57. Lizard-Nacol S, Lidereau R, Collin F, et al. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 1995;55:4416-9.
58. Stark A, Hulka BS, Joens S, et al. Her2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18:267-74. (Pubitemid 30056414)
59. van de Vijuer MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1998;10:1239-45.
60. Lodato RF, Maguire HC, Jr, Greene MI, et al. Immunohistochemical evaluation of c-erb B-2 oncogene expression in ductal carcinoma in-situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990;3:449-54.
61. Barnes DM, Bartkova T, Camplejohn RS, et al. Overexpression of the C-erb B-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992a;28:644-8.
62. DePotter CR, Schelfhout A-M, Verbeeck CKP, et al. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Hum Pathol 1995;26:601-6.
63. Lui E, Thor A, He M, et al. The Her2 (c-erb B-2) oncogene is frequently amplified in in situ carcinomas of breast. Oncogene 1992;7:1027-32.
64. Leal CB, Schmitt FC, Bento MJ, et al. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptor p53 and c-erb B-2 protein. Cancer 1995;75:2123-31.
65. Poller DN, Roberts EC, Bell JA, et al. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erb B-2 protein. Hum Pathol 1993;24:463-8. (Pubitemid 23145797)
66. Porter PL, Garcia R, Moe R, et al. C-erb B-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 1991;68:331-4.
67. Press MF, Hung G, Godolphin W, et al. Sensitivity of Her2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7. (Pubitemid 24173773)
68. Potten CS, Watson RJ, Williams GT. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988;58:163-70.
69. Joshi K, Smith JA, Perusinghe N, et al. Cell proliferation in the human mammary epithelium: differential contribution by epithelial and myoepithelial cells. Am J Pathol 1986;124:199-206. (Pubitemid 16016635)
70. Ferguson DJP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the resting human breast. Br J Cancer 1981;44:177-81. (Pubitemid 11039573)
71. Visscher DW, Gingrich DS, Buckley J, et al. Cell cycle analysis of normal atrophic and hyperplastic breast epithelium using two-color multiparametric flow cytometry. Anal Cell Pathol 1996;12:115-24. (Pubitemid 27007986)
72. Mohsin SK, Hilsenbeck SG, Allred DC. Estogen receptors and growth control in premalignant breast disease [Abstract 145]. Mod Pathol 2000a;13:28A.
73. De Potter CR, Praet MM, Slavin RE, et al. Feulgen DNA content and mitotic activity in proliferative breast disease: a comparison with ductal carcinoma in situ. Histopathology 1987;7:1307-19. (Pubitemid 18097847)
74. Hoshi K, Tokunaga M, Mochizuki M, et al. Pathological characterization of atypical ductal hyperplasia of the breast. Jpn J Cancer Chemother 1995;22(suppl 1):36-41.
75. Albonico G, Ouerzoli P, Feretti S, et al. Biophenotypes of breast carcinoma in situ defined by image analysis of biologic parameters. Pathology 1996;192:117-23. (Pubitemid 26104323)
76. Locker AP, Horrocks C, Gilmour AS, et al. Flow cytometric and histologic analysis of ductal carcinoma in situ of the breast. Br J Surg 1990;77:564-7. (Pubitemid 20164711)
77. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histologic classification association between cellular proliferation and c-erb B-2 protein expression. Mod Pathol 1994;7:257-62.
78. Bobrow LG, Happerfield LC, Gregory WM, et al. The classification of ductal carcinoma in situ and its association with biologic markers. Semin Diagn Pathol 1994;11:199-207. (Pubitemid 24308080)
79. Berardo MD, O'Connell POC, Allred DC. Biologic characteristics of premalignant and preinvasive breast disease. In: Pasqualini JR, Katzenellenbogen BS, eds. Hormone-dependent cancer. New York: Marcel Dekker; 1996:1-23.
80. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Cancer 1996;78:1403-16.
81. Rudas M, Neumayer R, Gnant M, et al. p53 protein expression cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997;33:39-44. (Pubitemid 27099565)
82. Querzoli P, Albonico G, Ferretti S, et al. Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer 1998;83:89-97. (Pubitemid 28299633)
83. Libby AL, O'Connell P, Allred DC, et al. Lobular carcinoma in situ: biologic features including loss of heterozygosity. Mod Pathol 1999;11:A112.
84. Siziopikou KP, Prioleau JE, Harris JR, et al. bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 1996;77:499-506.
85. Vakkala M, Paakko P, Soini Y. Expression of caspases 3, 6, and 8 is increased in parallel with apoptosis and histologic aggressiveness of the breast lesion. Br J Cancer 1999;81:592-9. (Pubitemid 29458853)
86. Zhu XL, Hartwick W, Rohan T, et al. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Mod Pathol 1998;11:1082-8. (Pubitemid 28525015)
87. Weinstat-Saslow D, Merino MJ, Marrow RE, et al. Overexpression of cyclin D. mRNA distinguishes invasive and in situ breast carcinomas from nonmalignant lesions. Nat Med 1995;1:1257-60.
88. Gillett CE, Lee AH, Millis RR, et al. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 1998;184:396-400.
89. Ariga N, Moriya T, Sizuki T, et al. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Jpn J Cancer Res 2000;91:1169-76.
90. Xu XC, Sneige N, Liu X, et al. Progressive decrease in nuclear retinoic and receptor beta messenger RNA level during breast carcinogenesis. Cancer Res 1997;57:4992-6. (Pubitemid 27498106)
91. Gobbi H, Dupont WD, Simpson JF, et al. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999;91:2096-101. (Pubitemid 30019570)
92. Deng G, Lu J, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057-2059. (Pubitemid 27020695)
93. Hosokawa T, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele specific expression. Genes Chromosomes Cancer 1988;22:66-71.
94. Lee W-H, Bookstein R, Hong F, et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-1399. (Pubitemid 17041661)
95. Wooster R, Heuhausen SL, Magnion J. Localization of a breast cancer susceptibility gene BRCA2 to chromosome 13q12-13. Science 1994;265:2088-2090. (Pubitemid 24325690)
96. Bern G, Cleton-Jansen A-M, Nollet F, et al. E-cadherin is a tumor/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14:6107-6115. (Pubitemid 26007298)
97. Deppert W, Gohler T, Koga H, Mutant p53 "gain of function" through pertubation of nuclear structure and function. J Cell Biochem 2000;35:115-22.
98. Gutmann D, Wood D, Collins F. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991;88:9658-9662. (Pubitemid 21915690)
99. Friedman LS, Ostermeyer EA, Lynch ED, et al. The search for BRCA-1. Cancer Res 1994;54:6374-6382.
100. O'Connell P, Pekkel V, Fuqua S, et al. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994;32:5-12. (Pubitemid 24322243)
101. O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703. (Pubitemid 28222144)
102. Rosenberg CL, Larson PS, Romo JD. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 1997;28:214-9. (Pubitemid 27069189)
103. Lakhani SR, Collins N, Stratton MR, et al. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48:611-5.
104. Lakhani SR, Slack DN, Hamoudi RA, et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferation. Lab Invest 1996;74:129-135. (Pubitemid 26041015)
105. Kasami M, Vnencak-Jones CL, Manning S, et al. Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 1997;150:1925-1932. (Pubitemid 27233066)
106. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997;150:297-303. (Pubitemid 27027118)
107. Rosenberg CL, de las Morenas A, Huang K, et al. Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest 1996;98:1095-100. (Pubitemid 26299920)
108. Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001;2410-4. (Pubitemid 32751643)
109. Radford DM, Fair KL, Phillips NJ, et al. Allelotyping of ductal carcinoma in situ of the breast: detection of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 1995;55:3399-3405.
110. Aldaz CM, Chen T, Sahin A, et al. Comparative allelotype of in situ and invasive human cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 1995;55:3976-3981.
111. Munn KE, Walker RA, Varley JM. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene 1995;10:1653-1657.
112. Stratton MR, Collins N, Lakhani SR, et al. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995;175:195-201.
113. Zhuang Z, Marino MJ, Chuaqua R, et al. Identical allelic loss on chromosome 11q13 in microdirected in situ and invasive human breast cancer. Cancer Res 1995;55:467-471.
114. Chappell SA, Walsh T, Walker RA, et al. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 1997;75:1324-1329. (Pubitemid 27179823)
115. Kuukasjärvi T, Minna T, Pennanen S, et al. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 1997;150:1465-1471. (Pubitemid 27152663)
116. James LA, Mitchell ELD, Menasce L, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and detection in common with invasive breast carcinoma. Oncogene 1997;14:1059-1065. (Pubitemid 27129250)
117. Nayar R, Zhuang Z, Merino MJ, et al. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol 1997;28:277-82. (Pubitemid 27106078)
118. Lakhani SR, Collins N, Sloane JP, et al. Loss of heterozygosity in lobular carcinoma in situ. J Clin Pathol Clin Mol Pathol 1995;48:M74-8.
119. Lu TJ, Osin P, Lakhani SR, et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998;58:4721-7. (Pubitemid 28480641)
120. Visscher DW, Wallis TL, Crissman JD. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics. Cancer 1996;77:315-20. (Pubitemid 26023351)
121. Sneige N, Sahin A, Dinh M, et al. Interphase cytogenetics in mammographically detected breast lesions. Hum Pathol 1996;27:330-5. (Pubitemid 26113814)
122. Werner M, Mattis A, Aubele M, et al. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive breast carcinoma. Virchows Arch 1999;435:469-72.
123. Cummings MC, Aubele M, Mattis A, et al. Increasing chromosome 1 copy number parallels histologic progression in breast carcinogenesis. Br J Cancer 2000;82:1204-10. (Pubitemid 30128880)
124. Murphy DS, Hoare SF, Going TJ, et al. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst 1995;87:1694-704.